Full-Time

Regional Business Director

Diabetes, Mid-Mountain

Posted on 9/11/2025

Deadline 2/2/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$180k - $240k/yr

+ Commission + Equity

Salt Lake City, UT, USA + 9 more

More locations: Des Moines, IA, USA | Wichita, KS, USA | St. Louis, MO, USA | Kansas City, MO, USA | Omaha, NE, USA | Tulsa, OK, USA | Oklahoma City, OK, USA | Minneapolis, MN, USA | Denver, CO, USA

Hybrid

Category
Sales & Account Management (1)
Requirements
  • Bachelor's Degree in the Health Sciences, Business/Marketing, Accounting, or related field; advanced degree preferred.
  • 8-10 years in bioscience commercial positions, including some but not limited to the following: sales representative, hospital representative, sales trainer, district manager, marketing manager, regional account manager, government affairs, and sales operations.
  • 3-5 years previous leadership experience required.
  • A valid, US State-issued driver’s license is required.
  • Frequent travel up to 50% domestically.
  • Position may require periodic evening and weekend work, as necessary to fulfill obligations.
Responsibilities
  • Work closely with management to establish corporate objectives specific to assigned region.
  • Deliver on corporate objectives specific to region.
  • With team and business partner input, develop, evolve, and execute regional business plans.
  • Eliminate or minimize barriers to progress, engaging the VP of Sales when appropriate regarding marketplace trends, business opportunities & threats, competitive information, and recommendations for addressing each.
  • Leverage internal expertise to maximize field impact.
  • Work with the Channel/Trade & Market Access Teams and other Regional Business Directors, to develop region-specific strategies for managed care accounts and reimbursement clarity.
  • Manage regional budget and resource allocations to maximize return on investment.
  • Hire and develop Territory Business Managers who will effectively advance Xeris’ business in alignment with strategic goals.
  • Identify and attract TBMs who will excel in the diabetes market (endo, ped. Endo, primary care, local diabetes chapters, hospitals, LTC, etc.).
  • Lead, teach, motivate and inspire a team of TBMs to achieve / exceed sales objectives in their assigned sales territory.
  • Engage TBMs frequently, including regular field visits & business reviews, listening to and coaching them to identify and maximize opportunities and leverage successes.
  • Foster a solution-orientation throughout the region.
  • Provide verbal and written feedback – positive and developmental – to foster a positive and productive environment of achievement that embraces personal accountability.
  • Recognize and reward strong performers, and coach employees performing below expectations, holding them accountable for improvement.
  • Develop, lead, and facilitate effective team sales meetings.
  • Create a face to the internal and external customer that demonstrates Xeris’ commitment to bringing value and solutions to the customers and patients we serve.
  • Collaborate with peers, marketing and training personnel to share information and implement regional initiatives/strategies.
  • Professionally and ethically represent Xeris to external customers and foster their respect by demonstrating our commitment to advancing patient care and outcomes.
  • Professionally and ethically represent Xeris internally and foster professionalism within, among, and beyond the team of TBMs.
  • Pre-launch: Engagement and profiling of key regional accounts (physicians, payers, PBMs, hospitals and other alternate site customers); post-launch: engagement with key accounts. Create, build and maintain relationships and regular communication with physicians and key thought leaders.
Desired Qualifications
  • Advanced degree preferred.
  • Recent experience managing key accounts (or leading teams doing the same) with experience in the diabetes market highly desirable.
  • Competencies: Leadership skills, Strategic thinking, Organizational skills, Self-directed, Strong Written and Verbal Communication skills, Decision-making skills, Customer Service focus, Analytical skills, Teamwork & Collaboration.
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $50M in Q1 2026 with 60% therapy-naïve patient starts.
  • ADA 2025 Standards explicitly recommend ready-to-use glucagon formulations, validating Gvoke positioning.
  • XP-8121 Phase 3 initiation in late 2026 targets $1B–$3B peak sales by 2035.

What critics are saying

  • Eli Lilly Baqsimi captures 65% glucagon market share; Gvoke revenue flat at $20.8M Q1 2026.
  • Medicare Part D redesign favors lowest-price glucagon options, sustaining Gvoke revenue pressure indefinitely.
  • CEO Paul Edick retires August 1, 2026; leadership transition disrupts Recorlev commercial expansion momentum.

What makes Xeris Pharmaceuticals unique

  • XeriSol and XeriJect platforms enable room-temperature stable, ready-to-use injectable formulations without reconstitution.
  • Diversified rare disease portfolio: Recorlev, Gvoke, Keveyis, and Ogluo across endocrinology and neurology.
  • Achieved profitability in 2025 with $60M adjusted EBITDA and 44% revenue growth year-over-year.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

ETF Daily News
Mar 29th, 2025
Cibc World Markets Corp Invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Cibc World Markets Corp invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS).

INACTIVE